1
|
Kciuk M, Yahya EB, Mohamed Ibrahim Mohamed M, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. Cancers (Basel) 2023; 15:2721. [PMID: 37345057 DOI: 10.3390/cancers15102721] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 05/09/2023] [Accepted: 05/10/2023] [Indexed: 06/23/2023] Open
Abstract
Cancer is among the current leading causes of death worldwide, despite the novel advances that have been made toward its treatment, it is still considered a major public health concern. Considering both the serious impact of cancer on public health and the significant side effects and complications of conventional therapeutic options, the current strategies towards targeted cancer therapy must be enhanced to avoid undesired toxicity. Cancer immunotherapy has become preferable among researchers in recent years compared to conventional therapeutic options, such as chemotherapy, surgery, and radiotherapy. The understanding of how to control immune checkpoints, develop therapeutic cancer vaccines, genetically modify immune cells as well as enhance the activation of antitumor immune response led to the development of novel cancer treatments. In this review, we address recent advances in cancer immunotherapy molecular mechanisms. Different immunotherapeutic approaches are critically discussed, focusing on the challenges, potential risks, and prospects involving their use.
Collapse
Affiliation(s)
- Mateusz Kciuk
- Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
- Doctoral School of Exact and Natural Sciences, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
| | - Esam Bashir Yahya
- Bioprocess Technology Division, School of Industrial Technology, Universiti Sains Malaysia, Penang 11800, Malaysia
| | | | - Summya Rashid
- Department of Pharmacology & Toxicology, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
| | - Muhammad Omer Iqbal
- Shandong Provincial Key Laboratory of Glycoscience and Glycoengineering, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China
| | - Renata Kontek
- Department of Molecular Biotechnology and Genetics, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland
| | - Muhanad A Abdulsamad
- Department of Molecular Biology, Faculty of Science, Sabratha University, Sabratha 00218, Libya
| | - Abdulmutalib A Allaq
- Faculty of Applied Science, Universiti Teknologi MARA, Shah Alam 40450, Malaysia
| |
Collapse
|
2
|
Delaunay T, Nader J, Grard M, Farine I, Hedwig V, Foloppe J, Blondy T, Violland M, Pouliquen D, Grégoire M, Boisgerault N, Erbs P, Fonteneau JF. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma. MOLECULAR THERAPY-ONCOLYTICS 2020; 18:573-578. [PMID: 32995481 PMCID: PMC7501423 DOI: 10.1016/j.omto.2020.08.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 08/19/2020] [Indexed: 12/01/2022]
Abstract
Malignant pleural mesothelioma (MPM) is a cancer of the pleura that lacks efficient treatment. Oncolytic immunotherapy using oncolytic vaccinia virus (VV) may represent an alternative therapeutic approach for the treatment of this malignancy. Here, we studied the oncolytic activity of VV thymidine kinase (TK)-ribonucleotide reductase (RR)-/green fluorescent protein (GFP) against MPM. This virus is a VV from the Copenhagen strain that is deleted of two genes encoding the TK (J2R) and the RR (I4L) and that express the GFP. First, we show in vitro that VVTK-RR-/GFP efficiently infects and kills the twenty-two human MPM cell lines used in this study. We also show that the virus replicates in all eight tested MPM cell lines, however, with approximately a 10-fold difference in the amplification level from one cell line to another. Then, we studied the therapeutic efficiency of VVTK-RR-/GFP in non-obese diabetic (NOD) severe combined immunodeficient (SCID) mice that bear peritoneal human MPM tumors. One intraperitoneal infection of VVTK-RR-/GFP reduces the tumor burden and significantly increases mice survival compared to untreated animals. Thus, VVTK-RR- may be a promising oncolytic virus (OV) for the oncolytic immunotherapy of MPM.
Collapse
Affiliation(s)
- Tiphaine Delaunay
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Joelle Nader
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Marion Grard
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | | | | | | | - Thibaut Blondy
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Mathilde Violland
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Daniel Pouliquen
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Marc Grégoire
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | - Nicolas Boisgerault
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| | | | - Jean-François Fonteneau
- CRCINA, INSERM, Université d'Angers, Université de Nantes, 44007 Nantes, France.,Labex IGO, Immunology Graft Oncology, 44007 Nantes, France
| |
Collapse
|